Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMAR1: [203Pb]VMT01 and [68Ga]VMT02 Imaging in Metastatic Melanoma
NCT04904120Phase 1Completed
- Sponsor
- Perspective Therapeutics, Inc.
- Start
- Mar 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in melanoma comparing [203Pb]VMT01 First with [68Ga]VMT02 First (2 arms). Primary endpoints: Number of Participants with Study Imaging Agent-Associated Adverse Events, Biodistribution of [68Ga]VMT02 at 12 hours and 5 more. Started Mar 2021; status: completed.
02
Drugs
[203Pb]VMT01Gallium Ga 68-VMT02
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04904120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04904120.